126. Morrissey PE, Shaffer D, Monaco AP, et al. Peripheral vascular disease after kidney-pancreas

transplantation in diabetic patients with end-stage renal disease. Arch Surg 1997;132:358–362.

127. Knight RJ, Schanzer H, Guy S, et al. Impact of kidney-pancreas transplantation on the progression

of peripheral vascular disease in diabetic patients with end-stage renal disease. Transplant Proc

1998;30:1947–1949.

128. Nakache R, Tyden G, Groth CG. Quality of life in diabetic patients after combined pancreas-kidney

or kidney transplantation. Diabetes 1989;38(suppl 1):40–42.

129. Gross CR, Limwattananon C, Matthees BJ. Quality of life after pancreas transplantation: a review.

Clin Transplant 1998;12:351–361.

130. Owen RJ, Ryan EA, O’Kelly K, et al. Percutaneous transhepatic pancreatic islet cell transplantation

in type 1 diabetes mellitus: radiologic aspects. Radiology 2003;229:165–170.

131. Lau H, Reemtsma K, Hardy MA. Prolongation of rat islet allograft survival by direct ultraviolet

irradiation of the graft. Science 1984;223:607–609.

132. Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: continued insulin reserve

provides long-term glycemic control. Diabetes 2002;51:2148–2157.

133. Sutherland DE, Matas AJ, Goetz FC, et al. Transplantation of dispersed pancreatic islet tissue in

humans: autografts and allografts. Diabetes 1980;29(suppl 1):31–44.

134. Brendel MD, Hering BJ, Schultz AO, et al, eds. International Islet Transplant Registry 2001. 2001;8:1.

135. Teuscher AU, Kendall DM, Smets YF, et al. Successful islet autotransplantation in humans:

functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes

1998;47:324–340.

136. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes

mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230–238.

137. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet

transplantation. N Engl J Med 2006;355(13):1318–1330.

138. Ryan EA, Paty BW, Senior PA, et al. Five year follow-up after clinical islet transplantation. Diabetes

2005;54:2060–2069.

139. Markmann JF, Kaufman DB, Ricordi C, et al. Financial issues constraining the use of pancreata

recovered for islet transplantation: a white paper. Am J Transplant 2008;8(8):1588–1592.

140. Close N, Alejandro R, Hering B, et al. Second annual analysis of the collaborative islet transplant

registry. Transplant Proc 2007;39:179–182.

141. Tiwari JL, Schneider B, Barton F, et al. Islet cell transplantation in type 1 diabetes: an analysis of

efficacy outcomes and considerations for trial designs. Am J Transplant 2012;12:1898–1907.

142. Shapiro AM. Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and

long-term outcome. Rev Diabet Stud 2012;9:385–406.

143. Ricordi C, Lacy PE, Firike EH, et al. Automated method for isolation of human pancreatic islets.

Diabetes 1988;37:413–420.

144. Linetsky E, Bottino R, Lehmann R, et al. Improved human islet isolation using a new enzyme blend,

LiberaseTM. Diabetes 1997;46:1120–1123.

145. Gerber PA, Pavlicek V, Demartines N, et al. Simultaneous islet-kidney versus pancreas–kidney

transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia

2008;51(1):110–119.

146. Kaufman DB, Baker MS, Chen X, et al. Sequential kidney/islet transplantation using prednisone-free

immunosuppression. Am J Transplant 2002;2:674–677.

147. Lakey JR, Warnock GL, Rajotte RV, et al. Variables in organ donors that affect the recovery of

1009

human islets of langerhans. Transplantation 1996;61:1047–1053.

148. Kneteman NM, Lakey JR, Kizilisik TA, et al. Cadaver pancreas recovery technique. Impact on islet

recovery and in vitro function. Transplantation 1994;58:1114–1119.

149. Lakey JR, Tsujimura T, Shapiro AM, et al. Preservation of the human pancreas before islet isolation

using a two-layer (UW solution-perfluorochemical) cold storage method. Transplantation

2002;74:1809–1811.

150. Ricordi C, Fraker C, Szust J, et al. Improved human islet isolation outcome from marginal donors

following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation

2003;75:1524–1527.

151. Hering BJ, Matsumoto I, Sawada T, et al. Impact of two-layer pancreas preservation on islet

isolation and transplantation. Transplantation 2002;74:1813–1816.

152. Paushter DH, Qi M, Danielson KK, et al. Histidine-tryptophan-ketoglutarate and University of

Wisconsin solution demonstrate equal effectiveness in the preservation of human pancreata

intended for islet isolation: a large-scale, single-center experience. Cell Transplant 2013; 22:1113–

1121.

153. Markmann JF, Deng S, Desai NM, et al. The use of non-heart-beating donors for isolated pancreatic

islet transplantation. Transplantation 2003;75:1423–1429.

154. Weimar B, Rauber K, Brendel MD, et al. Percutaneous transhepatic catheterization of the portal

vein: a combined CT- and fluoroscopy-guided technique. Cardiovasc Intervent Radiol 1999;22:342–

344.

155. Bretzel RG, Brandhorst D, Brandhorst H, et al. Improved survival of intraportal pancreatic islet cell

allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J Mol

Med 1999;77:140–143.

156. Citro A, Cantarelli E, Maffi P, et al. CXCR1/2 inhibition enhances pancreatic islet survival after

transplantation. J Clin Invest 2012;122:3647–3651.

157. Posselt AM, Szot GL, Frassetto LA, et al. Clinical islet transplantation at the University of

California, San Francisco. Clin Transpl 2010;235–243.

158. Paty BW, Ryan EA, Shapiro AM, et al. Intrahepatic islet transplantation in type 1 diabetic patients

does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin

independence. Diabetes 2002;51:3428–3434.

159. Radosevich DM, Jevne R, Bellin M, et al. Comprehensive health assessment and five-yr follow-up of

allogeneic islet transplant recipients. Clin Transplant 2013;27:E715–E724.

160. Rickels MR, Kong SM, Fuller C, et al. Improvement in insulin sensitivity after human islet

transplantation for type 1 diabetes. J Clin Endocrinol Metab 2013;98:E1780–E1785.

161. Frank A, Deng S, Huang X, et al. Transplantation for type I diabetes: comparison of vascularized

whole-organ pancreas with isolated pancreatic islets. Ann Surg 2004;240(4):631–640.

162. Hirsch D, Odorico J, Danobeitia JS, et al. Early metabolic markers that anticipate loss of insulin

independence in type 1 diabetic islet allograft recipients. Am J Transplant 2012;12(5):1275–1289.

163. Hirshberg B, Rother KI, Digon BJ 3rd, et al. Benefits and risks of solitary islet transplantation for

type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health

experience. Diabetes Care 2003;26:3288–3295.

164. Casey JJ, Lakey JR, Ryan EA, et al. Portal venous pressure changes after sequential clinical islet

transplantation. Transplantation 2002;74:913–915.

165. Rafael E, Ryan EA, Paty BW, et al. Changes in liver enzymes after clinical islet transplantation.

Transplantation 2003;76:1280–1284.

166. Esposito A, Palmisano A, Maffi P, et al. Liver perfusion changes occurring during pancreatic islet

engraftment: a dynamic contrast-enhanced magnetic resonance study. Am J Transplant 2014;14:202–

209.

167. Markmann JF, Rosen M, Siegelman ES, et al. Magnetic resonance-defined periportal steatosis

following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes

2003;52:1591–1594.

168. Piemonti L, Everly MJ, Maffi P, et al. Alloantibody and autoantibody monitoring predicts islet

transplantation outcome in human type 1 diabetes. Diabetes 2013;62:1656–1664.

169. Naziruddin B, Wease S, Stablein D, et al. HLA class I sensitization in islet transplant recipients:

1010

report from the collaborative islet transplant registry. Cell Transplant 2012;21:901–908.

170. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer

preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004;4:390–401.

171. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured

islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005;5(8):2037–

2046.

172. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: the UIC

protocol. Am J Transplant 2008;8:1250–1261.

173. Markmann JF, Deng S, Huang X, et al. Insulin independence following isolated islet transplantation

and single islet infusions. Ann Surg 2003; 237:741–750.

174. Keymeulen B, Gillard P, Mathieu C, et al. Correlation between b-cell mass and glycemic control in

type 1 diabetic recipients of islet cell graft. PNAS 2006;103(46):17444–17449.

175. Han D, Xu X, Pastori RL, et al. Elevation of cytotoxic lymphocyte gene expression is predictive of

islet allograft rejection in nonhuman primates. Diabetes 2002;51:562–566.

176. Shapiro AM, Hao EG, Lakey JR, et al. Novel approaches toward early diagnosis of islet allograft

rejection. Transplantation 2001;71:1709–1718.

177. Saudek F, Jirak D, Girman P, et al. Magnetic resonance imaging of pancreatic islets transplanted

into the liver in humans. Transplantation 2010;90:1602–1606.

178. Jacobs-Tulleneers-Thevissen D, Chintinne M, Ling Z, et al. Beta Cell Therapy Consortium EU-FP7.

Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of

mice leading to a pilot study in a type 1 diabetic patient. Diabetologia 2013;56:1605–1614.

179. Basta G, Montanucci P, Luca G, et al. Long-term metabolic and immunological follow-up of

nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts:

four cases. Diabetes Care 2011;34:2406–2409.

180. Vaithilingam V, Barbaro B, Oberholzer J, et al. Functional capacity of human islets after longdistance shipment and encapsulation. Pancreas 2011;40:247–252.

181. Luo JZ, Xiong F, Al-Homsi AS, et al. Allogeneic bone marrow cocultured with human islets

significantly improves islet survival and function in vivo. Transplantation 2013;95:801–809.

182. Yeung TY, Seeberger KL, Kin T, et al. Human mesenchymal stem cells protect human islets from

pro-inflammatory cytokines. PLoS ONE 2012;7:e38189.

183. Ding Y, Bushell A, Wood KJ. Mesenchymal stem-cell immunosuppressive capabilities: therapeutic

implications in islet transplantation. Transplantation 2010;89:270–273.

1011

SECTION C: HEAD AND NECK

1012

Chapter 41